The development of new excipient premixes marks a significant step forward for personalized compounding. Building on traditional excipient bases, the project delivered premixes with enhanced stability, solubility, and compatibility, validated across a wide range of APIs. More than seventy formulations were created using the standardized development process, cutting development time by more than half and enabling scalable expansion of individualized therapy options. This library, coupled with validated QC and stability protocols, provides a unique foundation for safe, rapid deployment of new patient-specific treatments.
Precision-scale integration within the PharmaPrinter has set a new benchmark for in-process control, ensuring 100% weight verification of each printed dose. Combined with the introduction of spectroscopic QC methods, such as validated NIR models for blend uniformity, the technology moves quality control from a manual, retrospective step into an automated, integrated part of the manufacturing process. This degree of assurance directly addresses regulatory expectations while providing confidence for pharmacists and healthcare providers.
Cloud integration via the Curify 2.0 platform advances the field beyond current compounding practice. Real-time connectivity supports centralized monitoring of devices, remote updates, and data-driven optimization of production. The platform has also been equipped with electronic signatures, audit trails, and role-based access to ensure compliance with Annex 11 and 21 CFR Part 11. Together, these features enable scalable, compliant, and efficient operations across multiple sites, while strengthening trust with regulators and healthcare systems.
The award of ISO 13485 certification in June 2024 confirms that the PharmaKit platform is not only technologically advanced but also built to international medical device standards. This achievement paves the way for wider clinical adoption and international market entry, demonstrating that automated, decentralized manufacturing of personalized medicines can be implemented in a regulated environment.
Looking ahead, the results achieved open new opportunities but also highlight key needs: continued development of spectroscopic QC models for additional APIs, expansion of cloud-based integrations with hospital information systems, and demonstration projects with healthcare providers to accelerate adoption. Equally, access to supportive regulatory frameworks, sustainable financing for scale-up, and strong IP protection will be critical to ensure broad uptake and long-term success.
